Data to Be Presented At ESMO 2008 Highlight Pfizer Inc. Commitment to Cancer Care and Research

STOCKHOLM, Sweden--(BUSINESS WIRE)--Pfizer announced today that important study results involving the company’s leading anticancer agent, SUTENT® (sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12—16 September 2008.

MORE ON THIS TOPIC